Based on the topline results from the EPCORE ® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss ...

AbbVie today announced topline results from the Phase 3 EPCORE® DLBCL-1 trial evaluating epcoritamab, a T-cell engaging ...

Durable complete responses with CAR-NK + Rituximab in patients who failed current standards of care in Waldenstrom’s ...

Cancer cells that detach from a primary tumor can remain hidden in the body for years in a dormant state, avoiding immune ...

The FDA has granted full approval to verdinexor tablets (Laverdia; Anivive Lifesciences) for the treatment of dogs with lymphoma. The approval gives veterinarians a promising new oral avenue for ...

Every time our body encounters a new disease-causing agent, a crucial defense system called adaptive immunity comes into play ...

The investigational cancer vaccine, NOUS-209, was found to safely stimulate the immune system to target precancerous and ...

CAR T cells have made headlines for their ability to fight hematological cancers, but they have proven largely ineffective ...

Acute graft-versus-host disease (aGVHD) is one of the most serious complications after allogeneic hematopoietic stem cell ...

Inflammation has to fight pathogens fast—but it can't get out of control. Researchers at the German Cancer Research Center ...

After JP Morgan, the company is focusing on getting ready to submit a biologics license application to the FDA for miv-cel in ...